Background-Biomarkers of atherosclerosis may refine clinical decision making in individuals at risk of cardiovascular disease. The purpose of the study was to determine the prognostic significance of endothelial function and other vascular markers in apparently healthy men. 
M easures of vascular function have emerged as potential surrogate markers of cardiovascular outcome. The endothelium plays a pivotal role in vascular homeostasis and if healthy abrogates atherosclerosis. 1 Microvascular dysfunction contributes to adverse cardiovascular sequelae, but its ability to predict future events has not been well studied. A measure of conduit vessel function, brachial artery flowmediated dilation (FMD) has been widely used as a research tool to evaluate endothelial function. 2 Indeed, FMD is impaired early and has been shown to have predictive value in subjects with or at high risk of vascular disease. 3 However, much less is known about the prognostic significance of FMD in apparently healthy subjects. In addition, the relationship between traditional cardiovascular risk factors and FMD is quite weak. 4 Recent evidence suggests that the relationship with risk factors is much stronger for microvascular hyperemic velocity, the stimulus for FMD. 5, 6 This has prompted a reevaluation of the optimal vascular marker for risk prediction.
Clinical Perspective on p 169
The Firefighters and Their Endothelium (FATE) study was a longitudinal prospective cohort evaluation of the relationship between biomarkers of vascular health and incident cardiovascular events in a group of healthy men at low to intermediate Framingham risk. 7 We report here the long-term follow-up of this cohort.
Methods

Patient Population
The study population consisted of 1574 male firefighters (mean age, 49.4Ϯ9.9 years) recruited from 4 research centers in Canada. Subjects were free of overt cardiovascular disease and had a low burden of cardiovascular risk factors. The study was approved by the ethics committee of each participating institution, and study participants provided written informed consent.
Study Protocol
The study protocol has been described previously. 7 Briefly, between March 1999 and October 2003, subjects underwent a baseline assessment of risk including fasting glucose, total cholesterol, triglycerides, and high-density lipoprotein cholesterol. Low-density lipoprotein was calculated from the Friedewald equation. A detailed interview and questionnaire documented demographics, traditional risk factors, exercise and dietary history, fire and smoke exposure, and family history. Physical examination characteristics included blood pressure, heart rate, height, weight, waist, and hip circumference. C-reactive protein (CRP) was measured using a highsensitivity assay with the Roche Diagnostics Tinaquant (latex) assay on a Hitachi 912 platform (Roche Diagnostics, Indianapolis, IN). Risk factors were defined according to current guidelines.
Risk Factor Definition
Current smoking was defined as daily cigarette smoking within the last year. Hypertension was deemed present if blood pressure was Ͼ140/90 mm Hg or the subject was on active antihypertensive therapy. Diabetes mellitus was defined as fasting glucose Ն7.0 mmol/L, self-report of diabetes, or the need for diabetes medications or insulin. A positive family history of premature coronary disease was defined as any first-degree relative with cardiovascular disease Ͻ60 years of age. The Framingham risk score (FRS) was based on the recently published risk engine that includes total cardiovascular risk. 8 
Brachial Artery Assessment of FMD and Hyperemic Velocity
A standardized brachial artery ultrasound protocol was used in the 4 research sites as previously reported. 4 Technical validation was done at each site by individuals from the core laboratory in Calgary. A blood pressure cuff was placed on the right upper arm above the antecubital fossa with a 5-minute occlusion time. On cuff release, hyperemic velocity was recorded for 30 seconds, and 2-dimensional imaging was resumed up to 2 minutes after cuff release. Baseline was reestablished and recorded, and sublingual nitroglycerin (0.4 mg) was administered to determine endothelium-independent vasodilation.
Videotapes were analyzed at the core laboratory in Calgary by a single technician blinded to demographic information. An automatic edge detection software program was use (DEA, Montreal, QC, Canada). In this study, the intraobserver variability for repeated measurements of FMD using the above approach was 0.7Ϯ0.7% with a coefficient of variation of 4.5%. FMD was expressed as percent FMD compared with baseline. The absolute increase in brachial diameter was also examined, but because it did not yield a different outcome, it was not included in the reported analysis. FMD corrected for shear stress was obtained by dividing FMD by the hyperemic velocity-time integral (VTI).
Hyperemic velocity was determined as the peak VTI of the first complete velocity envelope obtained after cuff release. Higher values represent better microvascular dilation. The intraobserver variability for VTI was 3.1Ϯ3.0 cm, yielding a coefficient of variation of 2.0%.
Vascular Reproducibility Cohort
To evaluate repeatability of FMD and VTI, 51 subjects underwent endothelial function testing 16Ϯ4 months after the baseline study. The coefficient of variation for FMD was 14.3% and for hyperemic VTI was 14.0%.
Ultrasound Assessment of Carotid Intima-Media
B-mode images of the right common carotid extending over 1 cm were obtained just proximal to the flow divider. A circumferential scan was performed, aimed at identifying the thickest region of the common carotid artery segment. A minimum of 3 frames were measured offline by 2 sonographers who manually traced the lumen-to-intima and the media-to-adventitia interfaces with locally developed software at the core laboratory in Hamilton, ON, Canada. 9 The primary measurement outcome was the mean intima-media thickness (IMT) of the frame with the largest measurement. Intraclass correlation coefficients within and between observers were 0.89 and 0.92.
Follow-Up and Cardiovascular End Points
Telephone follow-up was obtained for all subjects every 12 months. Documentation was obtained on events, verified by the local site investigator, and reviewed by the end-point committee. Of the 1574 participants, there were 18 subjects with non-end-point deaths and 15 subjects who were lost to follow-up or withdrew consent.
The primary end point was a composite of cardiovascular death; resuscitated cardiac arrest; nonfatal myocardial infarction; revascularization in the coronary, carotid, or peripheral circulation; symptomatic vascular disease with a Ͼ50% stenosis documented by angiography; and documented stroke or transient ischemic attack. The outcome variable was time to first of the composite cardiovascular events. The coprimary vascular variables were FMD and hyperemic VTI.
Data Analysis and Statistics
Descriptive statistics are expressed as meanϮSD or medians (25th to 75th percentile) for continuous variables and as percentages for categorical or binary variables. The data loss (not obtained) for the vascular end points and demographic data was 1% to 2%. KaplanMeier curves for the proportion who were free of the composite end point were estimated up to 9 years. Participants who died of unrelated causes or who were lost to follow-up before an event was observed were censored at the time of last observation, as were individuals who had Ͻ9 years of event-free follow-up.
Proportional Hazards Models
Initially, an individual proportional hazards model was fitted for each of the potential predictor variables, including the vascular markers with censored observations as described above. Continuous variables were logarithm transformed if necessary and standardized. Proportional hazards assumptions were confirmed with Schoenfeld residuals.
Comparison of Proportional Hazards Models When the Vascular Markers Were Added to the FRS
We compared test characteristics of different prediction models in which the baseline model contained only the FRS and the subsequent extended models included the FRS and each of the vascular variables separately and together. All continuous variables were standardized to enable comparison of coefficients.
Hazard ratios (HRs) were estimated for each of the regression models. The incremental statistical significance of each of the vascular markers when added to the FRS was evaluated with the likelihood ratio test. Discrimination was assessed with the Harrell C index. The C index for each extended model was compared with the C index for the baseline model using bootstrap sampling. The models were also compared through the use of the Bayes information criteria and the Akaike information criteria. The goodness of fit for each model was compared by use of the Nagelkerke likelihood ratiobased R 2 measure. Calibration was assessed with the Gronnesby and Borgan likelihood ratio test.
Risk Categories and Reclassification
From each regression model, the predicted probability of an event at 9 years was calculated. With this predicted probability, participants were stratified into 3 risk categories (Յ3%, Ͼ3% and Յ10%, and Ͼ10%). The predicted probabilities using the FRS alone for the sample were much lower than the estimated 10-year predicted risk using the FRS. The above cut points were chosen to coincide with the FRS categories of 10-year risk of Յ5%, Ͼ5% and Յ20%, and Ͼ20%. Reclassification tables (for 5 years of follow-up) were developed separately for those who had an event and those who did not have an event within 5 years, and the 5-year net reclassification improvement was calculated. 10 Observations censored before 5 years were omitted from the reclassification analysis. All subjects in the reclassification analysis had a minimum of 5 years of follow-up. The 5-year time point was chosen for the reclassification analysis because Ͻ5% of the observations were censored at this point in time and 71% of the events had been observed; by 6 years, the number censored had increased to 25% and the number of events to only 80%. By 8 years, 56% of the observations had been censored. The net clinical reclassification improvement was calculated using only those individuals at intermediate risk.
Results
Baseline Patient Demographics
The overall study cohort (nϭ1574) consisted of mainly middle-aged men (mean age, 49.4 years) with low to medium Framingham risk (Table 1 ). There was a low prevalence of smoking and diabetes mellitus, and only 15% of subjects were taking cardiovascular medications at baseline. The majority of these were for hypertension (11%) or lipid lowering (8%).
Cardiovascular Events
There were 111 events in 71 subjects during a mean follow-up of 7.2Ϯ1.7 years; 95% of the participants were followed up for at least 5 years. Events included 21 nonfatal myocardial infarctions and 41 revascularizations (28 percutaneous and 13 coronary bypass surgeries). A minority of the events were cerebrovascular (nϭ12) or peripheral vascular (nϭ1) in nature. During the course of follow-up, 27% of subjects were on drug therapy for hypertension and 25% for lipid lowering, including those on therapy at baseline.
Predictors of Cardiovascular Events
The individual predictors of cardiovascular events are presented in Table 2 
Comparison of Proportional Hazards Models
The FRS was significantly related to cardiovascular events (HR, 2.28 per SD; 95% CI, 1.82 to 2.87; PϽ0.001). Of the vascular risk markers, hyperemic VTI was protective (HR, . CRP was not an independent predictor of outcome in any of the multivariable models examined.
Discrimination and Calibration
The C index for FRS was 0.746. When tested alone, the C index for hyperemic VTI was 0.665, for carotid IMT was 0.672, and for CRP was 0.640. When the vascular parameters were added to the FRS, CRP did not change the C index (0.748). There was an increase in the C index with hyperemic VTI (0.761), carotid IMT (0.754), and their combination (0.768), but these increases did not achieve statistical significance. The effects of the vascular parameters on goodness of fit and calibration parameters are presented in Table 3 . The largest decreases in Akaike and Bayes information criteria were observed when both carotid IMT and hyperemic VTI were added to the FRS.
Reclassification Improvement
The 5-year net reclassification improvement was 11.6% (Pϭ0.044) for carotid IMT, 6.9% for hyperemic VTI (Pϭ0.24), and Ϫ0.48% for CRP (Pϭ0.93). The combination of hyperemic VTI, CRP, and IMT resulted in a net reclassification improvement of 14.8% (Pϭ0.043). The 5-year net clinical reclassification improvement in intermediate-risk patients was 18.0% for IMT (Pϭ0.034) and 28.7% for hyperemic VTI (PϽ0.001; Table 4 ). The combination of IMT and VTI created the highest net clinical reclassification improvement of 37.8% (Pϭ0.002). The calculation of reclassification for the addition of VTI to FRS is illustrated in Table 5 .
Discussion
We demonstrate for the first time an independent association with cardiovascular events and hyperemic brachial artery velocity, the microvascular stimulus for FMD, but not FMD itself in this primary prevention population. We also confirm carotid IMT and FRS as independent predictors of events. This study has important implications for the use of hyperemic velocity as a surrogate marker and ultimately for risk assessment. The vascular endothelium is well situated both to be adversely affected by injurious stimuli and to serve as a barometer of vascular health. 11 Through the release of factors such as nitric oxide, a healthy endothelium is antiatherogenic. It has been well documented that endothelial dysfunction is an early marker of atherosclerosis. 2 The present study was the first to show a significant relationship between hyperemic velocity and cardiovascular outcomes in a primary prevention population. Hyperemic velocity is a measure of microvascular function that is only partly related to endotheliumdependent nitric oxide release. 12 Additional determinants of hyperemia at the microvascular level include adenosine, K ϩ ATP channels, hyperpolarizing factors, and prostaglandins among others. VTI remained highly significant in a model that included FRS and carotid IMT. In addition, it favorably affected net clinical reclassification in intermediate-risk individuals. Although the optimal assessment of hyperemic velocity is not clear, we demonstrated this relationship by simply measuring the first hyperemic beat. 13 We have recently demonstrated that traditional risk factors are related to hyperemic velocity. 6 This was originally shown by Mitchell and colleagues. 5 In addition, Huang et al 14 demonstrated that hyperemic velocity and FMD were predictors of adverse outcomes in subjects undergoing noncardiac vascular surgery. Microvascular endothelial dysfunction in the coronary circulation assessed with acetylcholine has been associated with adverse cardiovascular outcomes in subjects with minimal coronary artery disease. 11, 15 Finally, attenuation of acetylcholine-mediated resistance vessel dilation in the forearm was associated with adverse events in subjects with coronary disease. 16, 17 The present study thus provides additional information for the use of vascular function as a valid surrogate of atherosclerosis risk.
The most commonly reported marker of endothelial function is FMD. In the present study, there was no relationship between attenuated FMD and cardiovascular outcomes. In addition, in previous studies from this cohort, we demonstrated minimal relationship between FMD and traditional cardiovascular risk factors, CRP, or carotid IMT. 18 The data from other earlier studies were mixed, but these studies tended to be smaller, retrospective, and from subjects with established disease or at high risk. 19 -23 More recently, Shimbo et al 24 demonstrated no relationship between FMD and cardiovascular outcomes in a primary prevention population. However, both the Cardiovascular Health Study (CHS) and the Multi-Ethnic Study of Atherosclerosis (MESA) have shown a significant relationship between FMD and cardiovascular outcomes in large cohorts. 3, 25 However, the magnitude of effect was small when added to traditional risk factors and only modestly altered reclassification indices. 25 The FATE cohort was distinctly different from the CHS and MESA cohorts in that the population studied was both younger and at lower cardiovascular risk. In addition, we used an upper arm cuff position for FMD determination. This has been suggested to reflect a less purely endotheliumdependent stimulus. 26 It is also possible that microvascular dysfunction and not FMD was predictive because it is an earlier marker in this healthy younger cohort.
The present study also confirmed the relationship between carotid IMT and adverse events. 27 This had been shown in a number of populations, but the present study was one of very few that evaluated both endothelial function and carotid IMT simultaneously. Both IMT and hyperemic VTI added complementary and incremental information to the FRS for the prediction models and reclassification. The present data thus suggest that a marker of both vascular function and structure will provide added prognostic information. This would be intuitive because they measure different aspects of the biology of atherosclerosis and are not well correlated. 18 Chan et al 20 were among the first to demonstrate added benefit of carotid IMT and FMD in a small study of subjects with CAD.
Finally, CRP was a univariate predictor of events in this cohort, but this was not sustained after the addition of FRS, unlike previous reports. 28, 29 Some recent studies have not demonstrated robust reclassification indices for CRP. 30 
Limitations
Several important limitations must be acknowledged. The determination of brachial vascular function was performed with the occluding cuff on the upper arm. Although there is no clear consensus, a majority of studies performed now use a forearm cuff position, and the results may have been different with this position. The determination of carotid IMT used a single-site measurement of the far wall of the right common carotid. It is acknowledged that there are several alternative approaches using more detailed carotid IMT assessment that may have yielded potentially stronger associations to risk. 31 Despite this, a strong and independent relationship was demonstrated in the present study. An important limitation concerns the numbers used for the reclassification analysis presented in Tables 4 and 5 . This analysis cannot include any censored observation. We chose the 5-year time point for this analysis because the data are quite complete at 5 years (Ͻ5% of the observations are censored) but become heavily censored after 5 years, and the large number of observations censored each year (eg, 317 observations were censored between 5 and 6 years) outweighs the small number of events that occurred (eg, 6 events occurred between 5 and 6 years). Thus, in the interpretation of the results of this reclassification analysis, it must be remember that the statistics represent the reclassification rate after 5 years of follow-up.
Implications
The present study provided novel information on the prognostic value of a relatively simple measure of microvascular function, hyperemic VTI, in risk stratification. First, these results add to the literature demonstrating that measures of vascular function are surrogate markers of atherosclerosis. This finding has implications for studies of atherosclerosis that use vascular end points as surrogates of risk. In addition, because VTI is more reliably measured than FMD and is less dependent on operator expertise, this measure has the potential to be translated into clinical practice. Individuals with abnormal IMT and VTI even when at low risk by FRS are at substantially higher risk for future cardiovascular events; combined, these relatively simple surrogate measures of vascular structure and function can identify individuals at increased risk for events. These observations will certainly need to be studied in other cohorts to determine the clinical utility of these measurements. Whether such measures can identify individuals more likely to benefit from pharmacological risk reduction requires formal evaluation. 32, 33 There are many surrogate markers of atherosclerosis risk that have not been well integrated into clinical practice.
Conclusions
In healthy men, hyperemic velocity, the stimulus for FMD, was associated with adverse cardiovascular outcomes. The strength of the association was additive to FRS and measures of structural atherosclerosis and resulted in significant reclassification of risk. This measurement may aid in risk stratification of low-to intermediate-risk subjects.
CLINICAL PERSPECTIVE
The endothelium plays a prominent role in vascular homeostasis and in health inhibits atherosclerosis formation and its complications. Conduit vessel function can be readily measured noninvasively by assessing flow-mediated dilation after a hyperemic stimulus. Blood flow at the tissue level determines organ viability and is controlled mainly at the microvascular level. Thus, there has been recent interest in measures of microvascular function and its clinical relevance. In the present study, we demonstrated in a large, long-term, prospective cohort of healthy men a number of important and novel findings. First, unlike some previous studies, flow-mediated dilation was not associated with vascular events. However, the hyperemic stimulus was an independent risk marker after Framingham risk score was considered. Second, carotid intima-media thickness was also associated with events, and this association remained after correction for Framingham risk and the hyperemic stimulus. This suggests that measures of both structure and microvascular function are risk predictors for adverse outcomes and provide synergistic information. The present study adds further evidence to the literature that these end points are surrogate measures of atherosclerosis outcomes and can be used in clinical research. Finally, because hyperemic velocity is a readily measured outcome variable, it has the potential to be incorporated into clinical care if further studies support our reported association. This would be most applicable to intermediate-risk individuals in whom additional testing has been advocated for clinical decision making.
